• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Praxis Precision Medicines, Inc. - Common Stock (NQ:PRAX)

54.97 +0.75 (+1.38%)
Streaming Delayed Price Updated: 1:49 PM EDT, Aug 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Praxis Precision Medicines, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
January 12, 2025
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
January 06, 2025
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
December 18, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Expert Ratings For Praxis Precision Medicine
December 12, 2024
 
Via Benzinga
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine
September 04, 2024
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Praxis Precision Medicine
August 05, 2024
 
Via Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
December 16, 2024
 
Via Benzinga
Praxis Precision Medicines to Present at Upcoming December Investor Conferences
December 03, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society Annual Meeting
November 26, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Three Upcoming November Investor Conferences
November 06, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2024 Financial Results
November 06, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Third Quarter 2024 Financial Results and Host Conference Call on Wednesday, November 6, 2024
November 01, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
September 26, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
September 05, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Philip Morris International To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Wednesday
September 04, 2024
 
Via Benzinga
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations
September 04, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines Touts Encouraging Data For Mid-Stage Epilepsy Drug
September 03, 2024
Praxis Precision Medicines reports positive Phase 2 EMBOLD study results for relutrigine in treating SCN2A and SCN8A developmental and epileptic encephalopathy, showing significant seizure reduction... 
Via Benzinga
Praxis Precision Medicines announces positive topline results from the EMBOLD study in SCN2A and 8A developmental epilepsies, highlighting the disease-modifying potential of relutrigine
September 03, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Topline Data from the Phase 2 EMBOLD Study of Relutrigine (PRAX-562) in SCN2A and SCN8A Developmental and Epileptic Encephalopathies on September 3, 2024
September 02, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
These Analysts Increase Their Forecasts On Praxis Precision Medicines After Q2 Results
August 14, 2024
 
Via Benzinga
PRAX Stock Earnings: Praxis Precision Medicine Beats EPS, Misses Revenue for Q2 2024
August 13, 2024
PRAX stock results show that Praxis Precision Medicine beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
August 13, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Praxis Precision Medicines to Announce Second Quarter 2024 Financial Results and Host Conference Call on Tuesday, August 13, 2024
August 05, 2024
From Praxis Precision Medicines, Inc.
Via GlobeNewswire
Are We Having Fun Yet? Stocks Sell Off On Massive Volume
August 03, 2024
In this video, I review the overall market, my game-plan with the indices, how our largest swings are holding up, and the stocks on my radar. 
Via Talk Markets
Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails
July 24, 2024
The companies are no longer developing their drug for essential tremor treatment. 
Via Investor's Business Daily
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
 
Via Benzinga
Quarterly & Long-Term Portfolios For The Win
July 06, 2024
What a day for Meta! I was planning to add to my position, but the volume was too low. I would have been shaken out of most of it for the swing before it could become this position trade. 
Via Talk Markets
Value Of Praxis Precision Medicines' Lead Program In Essential Tremor Alone Is Underappreciated: Analyst
June 24, 2024
Needham rates Praxis Precision Medicines Buy with a $145 target. Key programs include ulixacaltamide for essential tremor (Phase 3 results expected in 2024) and PRAX-628 for focal seizures. 
Via Benzinga
Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure
June 20, 2024
The companies are working on treatments for essential tremor, a tricky indication. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 20, 2024
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap